SAN DIEGO, May 22, 2018 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced the new PRECICE
STRYDE™ system from NuVasive Specialized
Orthopedics™ (NSO) was used in the first set of
patients by internationally recognized limb lengthening and
reconstruction expert Dr. Dror
Paley. Built on five years of clinical experience, PRECICE
STRYDE is a market-leading internal system available for stature
lengthening and limb reconstruction.
PRECICE STRYDE is NSO's third-generation limb lengthening system
and includes an implantable intramedullary nail, locking screws,
reusable instruments and a hand-held External Remote Controller
(ERC). STRYDE was recently cleared by the U.S. Food and Drug
Administration in April for use in both the tibia and femur.
Patients are now able to non-invasively lengthen or shorten the
implant to a prescribed length utilizing the ERC post-surgery from
their own home versus lengthy hospital stays. When used for stature
lengthening for cosmetic purposes, STRYDE can increase a patient's
height by more than three inches.
Dr. Paley is the founder and director of the Paley Orthopedic
& Spine Institute in West Palm Beach,
Fla., and is recognized as one of the most experienced
surgeons in the United States and
world in limb lengthening and deformity correction.
"The PRECICE STRYDE technology advances how I am able to treat
patients requiring limb reconstruction or those seeking to increase
their height, and I am excited to incorporate this into my
practice," said Dr. Paley, a board-certified orthopedic surgeon
specializing in limb lengthening and deformity correction. "I
continually seek to offer better clinical solutions to my patients,
and I am proud to have collaborated with NuVasive in the
development of this latest orthopedic advancement."
This new system aims to provide better and more tolerable
post-operative outcomes for patients undergoing limb lengthening.
Prior to this technology, a patient was only permitted to apply
30-50 pounds of weight on each leg, leading to a slow and lengthy
return to daily life and activities. With STRYDE's unique stainless
steel composition, patients are now able to apply 150-250 pounds of
weight on each leg depending on the device chosen and
post-operative care recommended by their physician. This offers
patients a potential for 200 percent or greater post-operative
weight-bearing activity compared to previous systems, and studies
have shown earlier weight bearing may lead to quicker healing times
in patients using the PRECICE system1. Next launch steps
include partnering with leading global limb lengthening surgeons to
demonstrate cosmetic stature lengthening viability with plans for a
limited launch in mid-2018 and the product more broadly available
in 2019.
"At NSO, we are excited to introduce PRECICE STRYDE to the
market, which is just the start of a long line of PRECICE products
in the next 18-months to further transform the orthopedic space and
offer better clinical outcomes for patients," said Massimo Calafiore, president of NSO. "There is
so much opportunity for us to address unmet clinical needs in the
orthopedic market—from limb reconstruction to stature
lengthening—this latest technology has the ability to drastically
improve how our surgeon partners treat their patients."
About NuVasive
NuVasive, Inc. (NASDAQ:
NUVA) is the leader in spine technology innovation, focused on
transforming spine surgery and beyond with minimally disruptive,
procedurally-integrated solutions designed to deliver reproducible
and clinically-proven surgical outcomes. The Company's portfolio
includes access instruments, implantable hardware, biologics,
software systems for surgical planning, navigation and imaging
solutions, magnetically adjustable implant systems for spine and
orthopedics, and intraoperative monitoring service offerings. With
over $1 billion in revenues, NuVasive
has an approximate 2,400 person workforce in more than 40 countries
serving surgeons, hospitals and patients. For more information,
please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA® platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described in NuVasive's news releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
1 Laubscher M, Mitchell C, Timms A, et al. Outcomes
following femoral lengthening: An initial comparison of the PRECICE
intramedullary lengthening nail and the LRS external fixator
monorail system. Bone Joint J 2016;98-B:1382–8.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-precice-stryde-system-used-in-first-patient-for-stature-lengthening-by-international-limb-lengthening-expert-300652375.html
SOURCE NuVasive, Inc.